Objective: To evaluate the incidence of depression and anxiety caused by pegylated interferon α (PegIFN-α) treatment for chronic hepatitis B (CHB) and assess the efficacy of intervention with escitalopram and alprazolam.
Methods: A total of 165 CHB patients receiving PegIFN-α-based treatment for 12 weeks were assessed for moderate to severe depression and anxiety using Patient Health Questionnaire (PHQ-9) and 7-item Generalized Anxiety Disorder Scale (GAD-7)]. The patients identified to have moderate to severe depression and anxiety treated with escitalopram or alprazolam and the psychological condition of the patients was assessed at the 2nd, 4th and 8th weeks of the treatments.
Results: In the 165 patients receiving PegIFN-α treatment, 51 patients developed moderate to severe psychiatric symptoms, incuding 37 (22.4%) with depression, 31 (18.8%) with anxiety, and 17 (10.3%) with both. The symptoms of depression and anxiety was both significantly improved by intervention with escitalopram (P=0.000); alprazolam was effective for anxiety (P=0.001) but did not produce obvious effects on depression (P=0.904). Nevertheless, alprazolam had a much better therapeutic effect than escitalopram on anxiety in these patients (t=-3.198, P=0.010).
Conclusion: Psychological symptoms are common in CHB patients receiving PegIFN-α treatment. The symptoms of depression and anxiety can be ameliorated by intervention with escitalopram and alprazolam, respectively.
目的: 分析长效干扰素（PegIFN）治疗慢性乙型肝炎（CHB）引发的精神心理异常发生率, 评估艾司西酞普兰和阿普唑仑干预对PegIFN所致抑郁和焦虑症状的疗效。
方法: 165例接受PegIFN治疗的CHB患者, 治疗12周后, 使用抑郁筛查量表（PHQ-9）和焦虑筛查量表（GAD-7）对其进行精神心理学评估; 对筛选出的中重度抑郁和中重度焦虑的患者, 采用艾司西酞普兰或阿普唑仑干预, 分别于干预用药后第2、4、8周随访抑郁和焦虑症状的缓解程度, 评估艾司西酞普兰和阿普唑仑分别对抑郁和焦虑的治疗效果。
结果: 经量表检出并由精神科医师确认, 37例为中重度抑郁, 发生率为22.4%;31例为中重度焦虑, 发生率为18.8%;其中, 合并中重度抑郁和中重度焦虑的有17例, 发生率为10.3%。艾司西酞普兰对抑郁和焦虑均有较好疗效（P=0.000）, 阿普唑仑对焦虑效果显著（P=0.001）, 但对抑郁效果不明显（P=0.904）; 在焦虑的改善方面, 阿普唑仑比艾司西酞普兰疗效要好（t=-3.198, P=0.010）。
结论: PegIFN引发的抑郁和焦虑症状在我国CHB患者中发生率较高, 应注意精神心理异常的评估; 及时使用艾司西酞普兰或者阿普唑仑对PegIFN引发的抑郁和焦虑症状有较好的疗效; 同时可明显提高患者接受PegIFN治疗的依从性。